Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiantianma refers to the fresh tuber of *Gastrodia elata* Blume, a parasitic orchid widely utilized in Traditional Chinese Medicine (TCM). Unlike the more common dried form (Tianma), Xiantianma is valued for its higher concentration of volatile oils and specific bioactive compounds, most notably gastrodin (4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside) and p-hydroxybenzyl alcohol. It is primarily indicated for neurological and cardiovascular conditions, including dizziness, headache, epilepsy, and hypertension. Mechanistically, it is thought to exert neuroprotective, sedative, and anticonvulsant effects by modulating the GABAergic system, antagonizing NMDA receptors, and reducing neuroinflammation through the inhibition of proinflammatory cytokines. It is extensively produced and marketed in China, particularly in the Yunnan province, as both a regulated pharmaceutical product and a functional food.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiantianma.